N-(trans-4-aminomethylcyclohexanecarbonyl)-L-phenylalanyl-4-aminophenyl acetic acid | 145680-98-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(trans-4-aminomethylcyclohexanecarbonyl)-L-phenylalanyl-4-aminophenyl acetic acid
• 英文别名: trans-4-aminomethylcyclohexanecarbonyl-Phe-4-carboxymethylanilide；Tra-Phe-APAA
• CAS: 145680-98-4
• 化学式: C₂₅H₃₁N₃O₄
• 分子量: 437.539
• InChiKey: MHXICYJVWPVGLT-ONTIZHBOSA-N

反应信息

• 作为产物：
  描述：

  Boc-Tra-L-Phe-4-benzyloxycarbonylmethylanilide 在 sodium hydroxide 、 苯甲醚 作用下， 以 甲醇 为溶剂， 反应 3.5h， 生成 N-(trans-4-aminomethylcyclohexanecarbonyl)-L-phenylalanyl-4-aminophenyl acetic acid
  参考文献：
  名称：

  Synthesis of trans-4-Aminomethylcyclohexanecarbonyl-L- and -D-phenylalanine-4-carboxymethylanilide and Examination of Their Inhibitory Activity against Plasma Kallikrein.

  摘要：

  根据结构活性关系研究，将反式-4-氨基甲基环己烷甲酰-L-苯丙氨酸-4-羧甲基苯胺（Tra-Phe-APAA）设计为选择性血浆激肽释放酶抑制剂并进行了合成。Tra-Phe-APAA对血浆激肽释放酶的抑制作用Ki值为0.81微摩尔，而对腺激肽释放酶、纤溶酶、尿激酶、因子Xa和凝血酶的抑制作用Ki值分别为>500、390、200、>500和>500微摩尔。然而，其立体异构体Tra-D-Phe-APPA对上述酶的抑制作用无法检测。

  DOI：

  10.1248/cpb.40.1814

文献信息

• TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE
  申请人：Steinmetzer Torsten

  公开号：US20100022781A1

  公开（公告）日：2010-01-28

  The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.

  该发明涉及一般式（I）的胰蛋白酶样丝氨酸蛋白酶抑制剂，除了抑制纤溶酶外，还抑制血浆激肽原，以及它们的制备和用作药物，优选用于治疗失血，特别是在高纤溶状态、器官移植或心脏手术干预，特别是心肺转流手术中，或作为纤维蛋白粘合剂的组分。
• Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein
  申请人：Sturzebecher Jorg

  公开号：US20060148901A1

  公开（公告）日：2006-07-06

  The invention relates to the use of acylated 4-amidino- or 4-guanidinobenzylamine in accordance with the general formula I P4-P3-P2-P1  (I), where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted or unsubstituted 4-amidino- or 4-guanidinobenzylamine group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for systemic administration as anticoagulants/-antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.

  本发明涉及使用通式IP4-P3-P2-P1的酰化4-氨基酰胺或4-鸟氨酰胺苯甲胺，其中，P4是单取代、多取代或未取代的苯甲磺酰基，P3是单取代、多取代或未取代的天然或非天然的D构型α-氨基酸或α-亚氨酸，P2是单取代、多取代或未取代的天然或非天然的L构型α-氨基酸或α-亚氨酸，P1是单取代、多取代或未取代的4-氨基酰胺或4-鸟氨酰胺苯甲胺基团，用于抑制血浆激酶（PK）、XIa因子和XIIa因子，特别是用于在合成表面上预防凝血的激活和全身给药作为抗凝血剂/-抗血栓剂，特别是用于预防在合成表面上凝血的激活以避免血栓栓塞事件的发生。
• SERINE PROTEASE INHIBITORS
  申请人：Steinmetzer Torsten

  公开号：US20130267467A1

  公开（公告）日：2013-10-10

  The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the prevention of blood loss, and as components of fibrin adhesives.

  本发明提供了制备和使用式子I所示的化合物的方法，这些化合物是人体纤溶酶和血浆卡利肌酶的抑制剂。这些化合物可用于预防失血，并作为纤维蛋白黏合剂的组分。
• ACYLATED 4-AMIDINO- AND 4-GUANIDINOBENZYLAMINES FOR THE INHIBITION OF PLASMA KALLIKREIN
  申请人：The Medicines Company (Leipzig) GmbH

  公开号：US20160257708A1

  公开（公告）日：2016-09-08

  The invention relates to the use of acylated 4-amidino- or 4-guanidinobenzylamine in accordance with the general formula I P4-P3-P2-P1  (I) where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted or unsubstituted 4-amidino- or 4-guanidinobenzylamine group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for systemic administration as anticoagulants/-antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.

  本发明涉及使用基于通式IP4-P3-P2-P1的酰化4-氨基酰胺或4-鸟氨酰胺苯甲胺类化合物，其中P4是单取代、多取代或未取代的苯甲磺酰基，P3是单取代、多取代或未取代的天然或非天然α-氨基酸或α-亚氨酸，为D构型，P2是单取代、多取代或未取代的天然或非天然α-氨基酸或α-亚氨酸，为L构型，P1是单取代、多取代或未取代的4-氨基酰胺或4-鸟氨酰胺苯甲胺基团，用于抑制血浆卡利肌酶（PK）、XIa因子和XIIa因子，特别是用于预防在合成表面上的凝血活化以及全身给药作为抗凝血剂/-抗血栓剂，特别是为了避免血栓栓塞性事件的发生。
• US8207378B2
  申请人：——

  公开号：US8207378B2

  公开（公告）日：2012-06-26